Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Small interfering RNA–mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema

Abstract

Neurodegeneration and brain edema are hallmarks of human malignant brain tumors. Here we show that genetic or pharmacological inhibition of the glutamate transporter xCT (Xc system, encoded by SLC7a11) in vivo leads to abrogated neurodegeneration, attenuated perifocal edema and prolonged survival. These results show a crucial role for xCT in glioma-induced neurodegeneration and brain edema, corroborating the concept that edema formation may be in part a consequence of peritumoral cell death.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Human gliomas show elevated xCT expression, and siRNA-mediated xCT silencing lessens neurotoxic glutamate abundance in vivo.
Figure 2: RNAi-mediated xCT silencing or pharmacological xCT inhibition alleviates tumor-induced brain edema and prolongs survival.

Similar content being viewed by others

References

  1. DeAngelis, L.M. N. Engl. J. Med. 344, 114–123 (2001).

    Article  CAS  Google Scholar 

  2. Hanahan, D. & Weinberg, R.A. Cell 100, 57–70 (2000).

    Article  CAS  Google Scholar 

  3. Maher, E.A. et al. Genes Dev. 15, 1311–1333 (2001).

    Article  CAS  Google Scholar 

  4. Papadopoulos, M.C. et al. Neuroscience 129, 1011–1020 (2004).

    Article  CAS  Google Scholar 

  5. Wick, W. & Kuker, W. Onkologie 27, 261–266 (2004).

    CAS  PubMed  Google Scholar 

  6. Jain, R.K. et al. Nat. Rev. Neurosci. 8, 610–622 (2007).

    Article  CAS  Google Scholar 

  7. Takano, T. et al. Nat. Med. 7, 1010–1015 (2001).

    Article  CAS  Google Scholar 

  8. Ye, Z.C. & Sontheimer, H. Cancer Res. 59, 4383–4391 (1999).

    CAS  PubMed  Google Scholar 

  9. Sato, H. et al. J. Biol. Chem. 280, 37423–37429 (2005).

    Article  CAS  Google Scholar 

  10. Shih, A.Y. et al. J. Neurosci. 26, 10514–10523 (2006).

    Article  CAS  Google Scholar 

  11. Patel, S.A. et al. Neuropharmacology 46, 273–284 (2004).

    Article  CAS  Google Scholar 

  12. Chung, W.J. et al. J. Neurosci. 25, 7101–7110 (2005).

    Article  CAS  Google Scholar 

  13. Ishiuchi, S. et al. J. Neurosci. 27, 7987–8001 (2007).

    Article  CAS  Google Scholar 

  14. Ishiuchi, S. et al. Nat. Med. 8, 971–978 (2002).

    Article  CAS  Google Scholar 

  15. Verkman, A.S. et al. Biochim. Biophys. Acta 1758, 1085–1093 (2006).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank N. Scheufler, J. Csupor, S. Seufert, R. Schneider and H. Hilkman for experimental support. We further thank P.W. Kalivas (Medical University of South Carolina, Charleston, USA) for the antibody to xCT antibody and for sharing unpublished data, M. Conrad (German Research Center for Environmental Health, München, Germany) for the human and mouse xCT expression constructs, B.I. Kanner (Hebrew University Jerusalem, Israel) and G. Pietrini (Consiglio Nazionale delle Ricerche, Milano, Italy) for the GLT-1 expression construct and H. Sontheimer for providing details on the glutamate estimation. We acknowledge F. Mouttet and D. Peleg-Raibstein for technical support. We gratefully acknowledge members of M. Schwab's laboratory, J.R. Halstead and members of the H3 lab for helpful comments on the manuscript. E.H. is supported by the Köln Fortune Program of the Medical Faculty University Cologne and the Wilhelm Sander-Stiftung (WSS 2008.010.1). This study was funded by The International Human Frontiers Science Program Organization (to N.E.S.) and the Wilhelm Sander-Stiftung (WSS 2005.089.1 to I.Y.E.).

Author information

Authors and Affiliations

Authors

Contributions

N.E.S. and I.Y.E. conceived and designed the experiments; N.E.S., A.H., E.H. and I.Y.E. performed the in vitro experiments and contributed to the molecular cloning; N.E.S., T.E. and I.Y.E. performed the in vivo experiments; N.E.S., E.H., A.D., O.G., C.N., M.B. and I.Y.E. analyzed the data and contributed to techniques and analysis systems; N.E.S. and I.Y.E. wrote and edited the manuscript.

Corresponding authors

Correspondence to Nicolai E Savaskan or Ilker Y Eyüpoglu.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–5 and Supplementary Methods (PDF 682 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savaskan, N., Heckel, A., Hahnen, E. et al. Small interfering RNA–mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 14, 629–632 (2008). https://doi.org/10.1038/nm1772

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1772

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing